DexCom

YTD

ALL

Trade DexCom 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About DXCM

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE.

CEO

Jacob S. Leach

CEOJacob S. Leach

Employees

11,100

Employees11,100

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1999

Founded1999

Employees

11,100

Employees11,100

DXCM Key Statistics

Market cap

27.85B

Market cap27.85B

Price-Earnings ratio

31.12

Price-Earnings ratio31.12

Dividend yield

—

Dividend yield—

Average volume

6.71M

Average volume6.71M

High today

$74.92

High today$74.92

Low today

$71.53

Low today$71.53

Open price

$74.02

Open price$74.02

Volume

1.94M

Volume1.94M

52 Week high

$89.98

52 Week high$89.98

52 Week low

$54.11

52 Week low$54.11

Stock Snapshot

As of today, DexCom(DXCM) shares are valued at $72.18. The company's market cap stands at 27.85B, with a P/E ratio of 31.12.

As of 2026-06-04, DexCom(DXCM) stock has fluctuated between $71.53 and $74.92. The current price stands at $72.18, placing the stock +0.9% above today's low and -3.7% off the high.

The DexCom(DXCM)'s current trading volume is 1.94M, compared to an average daily volume of 6.71M.

In the last year, DexCom(DXCM) shares hit a 52-week high of $89.98 and a 52-week low of $54.11.

DXCM News

Nasdaq 50m

DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026?

Key Points DexCom is a leading innovator in the continuous glucose monitoring market with a global footprint across 52 countries. Insulet dominates the tubele...

TipRanks 4h

DexCom to present new clinical findings, advancements at ADA’s Sessions

DexCom (DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforcing its commitment to improving care for peopl...

Simply Wall St 3d

Assessing Dexcom Valuation After FDA Software Defect Recall And Investor Reaction

The FDA enforcement report on a software defect in several Dexcom (DXCM) CGM iOS and watchOS apps has pushed product reliability and recall risk to the foregrou...

Analyst ratings

84%

of 31 ratings

Buy

83.9%

Hold

16.1%

Sell

More DXCM News

Simply Wall St 5d

How Investors May Respond To DexCom Global App Recalls Over Delayed Glucose Alerts

In April 2026, Dexcom voluntarily initiated Class II global recalls of its G7, ONE and ONE+ iOS and watchOS CGM apps after an FDA enforcement report highlighted...

TipRanks 7d

Dexcom Shareholders Approve Board, Auditor and Compensation

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

People also own

Based on the portfolios of people who own DXCM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.